Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent in English~* Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for ASD or International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD10) criteria for Autism diagnosis confirmed by Autism Diagnostic Observational Schedule (ADOS-2) criteria~* Social Responsiveness Scale, second edition (SRS-2) (T-score) \>= 66~* Clinical Global Impressions of Severity (CGI-S) \>= 4 (moderately ill) at screening~* IQ \>= 70 as assessed by Wechsler Abbreviated Scale of Intelligence Scale: Second Edition (WASI-II) or Wechsler Preschool and Primary Scale of Intelligence: Fourth Edition (WPPSI-IV) intelligence test~* Language, hearing, and vision compatible with the study measurements as judged by the investigator~Inclusion Criteria for the OLE:~* Have completed the blinded treatment phase of the study OR were required to stop dosing at or before Week 8~* Have no adverse events that would prohibit starting the OLE~Exclusion Criteria:~* Initiation of a major change in psychosocial intervention (including investigational) within 4 weeks prior to screening~* Unstable or uncontrolled clinically significant psychiatric and/or neurological disorder that may interfere with the safety or efficacy endpoints~* Known personal or family history of cerebral aneurysm~* Risk of suicidal behavior~* Seizure within the past 6 months~* Medical history of alcohol or substance abuse/dependence~* Concurrent cardio-vascular disease not considered well controlled by the Investigator~* Clinically significant abnormality on electrocardiogram at screening~* Concomitant disease or condition (pulmonary, gastro-intestinal, hepatic, renal, metabolic, immunological system, or obesity that could interfere with the conduct of the study~* Evidence for current gastro-intestinal bleeding, e.g., active stomach ulcer disease~* History of coagulopathies, bleeding disorders, or blood dyscrasias~* Positive serology for hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) 1, or HIV 2~* Confirmed clinically significant abnormality in parameters of hematology, clinical chemistry, coagulation, or urinalysis~* Medical history of malignancy if not considered cured~* Participation in an investigational drug study within 90 days or 5 times the half-life of the investigational molecule (whichever is longer) prior to randomization~* Loss of blood over 250 milliliters within three months prior to screening~* Allowed medications have not been stable since 4 weeks before screening, and allowed medications for treatment of epilepsy have not been stable since 3 months before screening~* Use of prohibited medications within 2 weeks prior to screening visit or 5 times the half-life prior to randomization (whichever is longer)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
- Balovaptan (RO5285119) 10 mg/d equivalent (Type: EXPERIMENTAL): Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
- Balovaptan (RO5285119) 4 mg/d equivalent (Type: EXPERIMENTAL): Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks. This arm is open only to those participants enrolled prior to Version 6 of the study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy